← All trials
NCT04464967
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- Jul 9, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 154
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NKMAX Co., Ltd.Lead sponsor
- NKMAX Co., Ltd.Study director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Genes, erbB-2
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.